HCV Replication Inhibiting Compounds

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Hepatitis C virus (HCV) infection, such as those using peginterferon-alpha and ribavirin, suffer from substantial limitations in efficacy and tolerability, with many patients experiencing side effects and inadequate viral elimination.

Innovation Solution

Development of compounds represented by Formulae I, II, and III, and their pharmaceutically acceptable salts, which inhibit HCV replication by contacting infected cells or administering them to patients, potentially combined with other therapeutic agents like HCV helicase, polymerase, or NS5A inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If peginterferon-alpha and ribavirin are used to treat HCV infection, then viral elimination is achieved to some extent, but side effects and tolerability deteriorate substantially

Engineering Contradiction:

Improveviral elimination efficacyVSAvoidside effects and tolerability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent develops novel compounds with specific chemical structures (Formulae I, II, and III) that target HCV replication independently from the interferon-ribavirin pathway, segmenting the therapeutic approach into distinct mechanistic categories that avoid overlapping toxicity

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent modifies chemical parameters of antiviral compounds by developing specific molecular structures with defined substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11) to optimize antiviral activity while reducing off-target effects that cause side effects

Inventive Principle:

Principle #35Parameter changes

2Productivity

If peginterferon-alpha and ribavirin are used to treat HCV infection, then some viral elimination is achieved, but treatment efficacy deteriorates due to inadequate viral clearance

Engineering Contradiction:

Improveviral clearance rateVSAvoidoverall treatment efficacy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent describes compounds designed for continuous antiviral action against HCV replication, maintaining sustained inhibition of viral polymerase activity to achieve continuous viral clearance throughout the treatment period

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent combines multiple therapeutic agents including HCV helicase inhibitors, polymerase inhibitors, protease inhibitors, and NS5A inhibitors into composite treatment regimens that work synergistically to enhance viral clearance efficacy

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS9163017B2Anti-viral compounds

Publication Date: 2015.10.20 ABBVIE INC

AI summary

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.